

Outlook

With the global recovery well underway, many analysts are now predicting as much as 3% growth for the global economy. The global inventory rebuild as well as the continued impact of the stimulus policy that was introduced in 2009 are expected to be key drivers of growth. Elsewhere labour markets are also showing initial signs of stabilising albeit at very lower levels, while companies have also indicated that they are planning to increase capital spending in 2010. Despite this, investors need to be aware of the risks that can at the very least curb the potential growth rate of the economy. Firstly, the consumer in many of the developed economies will continue to repay the excess debt levels and hence curb their consumer spending habits. Governments around the world have unprecedented requirements to finance their spending and as a result many countries will have to adopt tighter fiscal policies to bring these excessive deficits lower. This will be accompanied by increased government bond issuance. As a result, equity markets should continue to benefit from the improved outlook, albeit at a more modest pace than seen in 2009, however signs for fragility in the economy could disrupt this rally suddenly.

If you have any further enquiries please do not hesitate to contact EBS Savings and Investments on 1850-203636.

DISCLOSURE:-

Irish Life Investment Managers Limited is authorised by the Financial Regulator. While Irish Life Investment Managers uses reasonable efforts to ensure that the information contained in this document is current, accurate and complete at the date of publication, no representations or warranties are made (express or implied) as to the reliability, accuracy or completeness of such information. Irish Life Investment Managers therefore cannot be held liable for any loss arising directly or indirectly from the use of, or any action taken in reliance on, any information contained in this document. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. The performance shown represents past performance and does not guarantee future results. Past performance is not indicative of future results.

Summit Asset Management is regulated by the Financial Regulator.

January 2010

Summit Mutual Funds

Quarterly Review

Equity markets continued to rally through the fourth quarter although returns were more modest than the sharp rebounds experienced through the second and third quarters from the March lows. The earnings season in the US exceeded expectations with most of this driven by cost cutting which led to further earnings upgrades post results. While economic releases globally were more mixed than recent quarters, the overall bias to releases and forecasts was upwards with more solid growth being forecast for 2010. Markets turned slightly negative in October with suggestions that monetary authorities around the globe may start outlining exit strategies in relation to the various stimulus measures which had been implemented through the year to support economies and the functioning of the financial system.

Following central bank meetings in early November when policy makers confirmed their commitment to maintain low levels of interest rates and not to withdraw liquidity support, markets began to rebound again. Confirmation at the G20 summit that fiscal policies would also remain supportive of growth and similar statements of intent from Asian policy makers further emphasised that various global support programmes would remain in place and helped to contribute to additional gains in markets.

The announcement by Dubai at the end of November that it was seeking to postpone debt repayments gave rise to concerns over new potential losses for the banking industry and fears over the credit worthiness of some perceived weaker sovereign debt issuers. Equity markets initially fell but as it appeared the problem would be contained with the UAE central bank providing liquidity to banks in the region and Abu Dhabi committing up to \$10bn in support for Dubai, markets began to recover again through December as contagion across the region and global markets was limited. Markets rallied into year end with new highs for the year being reached as the year drew to a close as assets were allocated to equities.

Through the quarter, most major international markets showed gains with the US up 5.5%, UK 4.8%, Europe 4.7% and the Pacific Basin -0.2%. Japan was marginally down, falling 0.2%. Ireland fell 11.1% as delays emerged in the transfer of loans from the banks to NAMA while the discounts to be paid for the loans being transferred rose. There were also suggestions that the government may be forced to take stakes of up to 50% in the two major banks.

During the quarter, commodities were the best performing stocks as commodity prices rose on the improving economic outlook. The technology sector also outperformed, also benefiting from the macro backdrop and signs that demand was improving in some sub sectors. Healthcare outperformed on positive product news flow and the completion of large scale mergers. Financials were the worst performing sector given the ongoing capital raisings in the sector and the announcement of initial proposals on capital requirements which were more onerous than expected and could result in additional capital raisings to enable banks meet the more strict guidelines. Defensive areas such as telecoms and utilities also underperformed.



Summit Balanced Fund


Review

Equities, 62.57%, **Fixed Interest** 29.57% & **Cash** 7.86%

During the quarter we purchased **Sainsbury**, the UK food retailer was bought given its defensive characteristics, financial strength, improving market share position and ongoing restructuring efforts. The stock has strong asset backing given its ownership of much of its store base and generates good free cash flow. We also bought **Amgen**, a US biotechnology company given its attractive valuation, strong potential from its osteoporosis treatment which is in development and strong EPO franchise.

Stocks sold included WPP, the advertising and marketing company, KBC, the Belgian bank, SAB Miller, the beverage company,

| Equity Sector Distribution | % | Top 10 Holdings | % |
|----------------------------|--------|-----------------|-------|
| Financials | 31.43% | CRH | 2.43% |
| Industrials | 13.41% | Ryanair | 0.94% |
| Telecomms and Technology | 10.32% | BP | 0.74% |
| Consumer Staples | 10.13% | HSBC | 0.74% |
| Energy | 8.94% | E. ON AG | 0.69% |
| Pharmaceuticals | 8.44% | Kerry Group | 0.66% |
| Food Retail and Misc | 6.34% | Bayer | 0.66% |
| Capital Goods | 6.90% | BNP Paribas | 0.64% |
| Utilities | 4.09% | Microsoft | 0.62% |
| | | Vodafone Group | 0.60% |



Bid/Exit price at 31/12/09
125.2c

***Past Performance**
1 Year — 22.42%
2 Year — -6.11%
5 Year — 1.28%
10 Year — N/A

Source: Moneymate ©
Annualised Performance


Summit Growth Fund

Review

Stocks which were bought during the quarter included **Reed Elsevier**, the professional publisher which was trading at a par with peers despite the relatively high quality of its assets. It has strong market positions in markets with reasonably good long term growth prospects with fewer structural risks than peers and good cash flow generation. Following a rights issue the balance sheet is strong and capable of underpinning a healthy dividend. We bought **BAE Systems**, the aerospace and defence company. The stock was trading at absolute and relative low valuation levels compared to peers with a strong balance sheet.

Stocks sold included Yara International, a Norwegian fertilizer company and Constellation Brands, a US beverage company.

| Equity Sector Distribution | % | Top 10 Holdings | % |
|----------------------------|--------|-------------------|-------|
| Financials | 27.33% | CRH | 3.58% |
| Food Retail and Misc | 10.38% | Novartis | 1.26% |
| Industrial | 11.37% | E on AG | 1.11% |
| Telecomms and technology | 11.23% | HSBC | 1.11% |
| Consumer Staples | 9.94% | BP | 1.04% |
| Capital Goods | 7.75% | Ryanair | 0.99% |
| Energy | 9.08% | Kerry Group | 0.97% |
| Pharmaceuticals | 8.51% | Royal Dutch Shell | 0.94% |
| Utilities | 4.41% | IBM | 0.94% |



Bid/Exit price at 31/12/09
113.30c

***Past Performance**
1 Year — 32.94%
2 Year — -13.49%
5 Year — -1.11%
10 Year — N/A

Source: Moneymate ©
Annualised Performance


Summit Global Leaders Fund

Review

During the quarter we bought **Abbott Laboratories**, the US healthcare company. The company offers good sales potential through Humira, its auto immune disease treatment. Strong trends are also evident in other key products. The company offers strong growth in cash flows, margin expansion opportunities and has cost cutting initiatives underway. Synergies from recent acquisitions are likely. We also bought **France Telecom** which was at attractive valuation levels. The company is looking for in-market consolidation opportunities and has recently completed a number of good deals. It formed a JV with T-Mobile in the UK. We sold the position in Samsung Electronics, the Korean electronics company.

Over the quarter, Oracle, the software company, rose 17.7% as profits exceeded expectations and the company said it is seeing a recovery in demand as customers are back spending again on IT. BHP Billiton gained 16.8% as commodity prices continued to improve.

| Equity Sector Distribution | % | Top 10 Holdings | % |
|----------------------------|--------|-------------------|-------|
| Telecomms and Technology | 27.62% | EXXON MOBIL | 4.78% |
| Energy | 17.91% | MICROSOFT | 3.51% |
| Pharmaceuticals | 14.99% | HSBC | 2.89% |
| Consumer Staples | 12.16% | APPLE | 2.75% |
| Financials | 18.74% | BP | 2.74% |
| Food Retail and Misc | 1.79% | JOHNSON & JOHNSON | 2.69% |
| Capital Goods | 3.58% | PROCTER & GAMBLE | 2.68% |
| Utilities | 1.30% | NESTLE | 2.67% |
| Industrial | 1.91% | IBM | 2.61% |
| | | AT & T | 2.44% |




Bid/Exit price at 31/12/09
80.30c

***Past Performance**
1 Year — 17.74%
2 Year — -12.65%
5 Year — -3.11%
10 Year — N/A

Source: Moneymate ©
Annualised Performance

Fund Performance

Performance Report - 04 May 2001 to 01 January 2010



Ex-Dividend Date. Past Performance is not necessarily a guide to future performance. Unit prices may fall as well as rise.